AUG 15, 2019 6:26 AM PDT

Drug Targets Early Instigators of Alzheimer Disease

WRITTEN BY: Nouran Amin

The two solidifying instigators of Alzheimer -disease (AD)—amyloid beta and the tau protein—have long been the topic of study for AD researchers. Amyloid beta contributes to AD by solidifying into toxic plaques that accumulate in the extracellular spaces of nerve tissue and the tau protein will tangle in the bodies of neurons affecting their function. These plaques and tangles are the hallmarks of AD and as a result studies are always looking for initiating drug development that targets these hallmarks.

Learn more on Alzheimer Disease:

Previous studies involving therapeutic development for AD specifically for targeting the hallmarks has often faced failure and the challenge to reverse cognitive decline as result of the disease remains at the forefront of research. Now, at the Arizona Center for Drug Discovery based at the UA College of Pharmacy, researchers have examined a molecule drug called ‘DYR219’ as a possible therapeutic for AD. DYR219 is believed to be unique in its ability to not target the hallmarks of AD but instead acts on the pathways that leads to these hallmarks. In other words, the drug acts as a prevention instead of a treatment.

“If you can block that process early, you can delay the downstream aggregation and formation of the pathologies,” says Travis Dunckley, a researcher at the ASU-Banner Neurodegenerative Disease Research Center.

Findings of the study were published in the journal Molecular Neurobiology and describes how the inhibitive effects of DYR219, or a similar drug, can eventually place a stop to AD development. By preventing or delaying the development of AD pathologies, DYR219 or a similar drug may halt the progression of Alzheimer’s in its tracks, before it damages the brain beyond repair.

“We showed a robust and significant delay in the onset of amyloid and tau pathology,” Dunckley says. “The reason I’m excited about this, especially in the face of a lot of the recent high profile clinical trial failures, is that this is really a different approach to treating the disease.”

Essentially, the drug works as a preventive measure by inhibiting a particular neuroactive enzyme called DYRK1 that holds crucial role in plaque and tangle formation in AD.

DYR219 is a powerful new drug developed to inhibit a kinase known as DYRK1. The inhibition targets leading pathologies of with Alzheimer's disease—plaques, (caused by the protein amyloid beta) and tangles, (caused by the tau protein). The drug can open new doors to preventing cognitive decline. Credit: Arizona State University, Graphic by Shireen Dooling

Source: Biodesign @ Arizona State University

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 07, 2020
Cancer
MAY 07, 2020
Yet Another Cancer Linked Tyrosine Kinase
In a cell, there are tens of thousands of individual components. Each component has a specific activity or role that the ...
MAY 12, 2020
Cannabis Sciences
MAY 12, 2020
Study Shows Cannabis May Block COVID-19 Infection
Researchers from the University of Lethbridge, Canada, have found that cannabis may be able to block COVID-19 infections ...
MAY 25, 2020
Genetics & Genomics
MAY 25, 2020
FDA Approves the First Treatment for Neurofibromatosis 1
In a major breakthrough, the Food and Drug Administration has approved a treatment for a genetic disorder called neurofi ...
MAY 23, 2020
Chemistry & Physics
MAY 23, 2020
Improving the understanding of GPCRs functioning
New research reported in Current Opinion in Structural Biology combines structural and spectroscopic approaches to garne ...
MAY 30, 2020
Cancer
MAY 30, 2020
Linking an Aggressive Tumor Factor to the Innate Immune Response
Epithelial Ovarian Cancer (EOC) is a cancer of the fallopian tubes with a low five-year survival rate with a tendency to ...
MAY 28, 2020
Cannabis Sciences
MAY 28, 2020
Cannabis-Free CBD More Effective than Regular CBD
Commonly known to come from the cannabis plant or hemp, cannabidiol (CBD) can also be found in a range of other plants. ...
Loading Comments...